Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00745550
Registration number
NCT00745550
Ethics application status
Date submitted
2/09/2008
Date registered
3/09/2008
Date last updated
20/04/2012
Titles & IDs
Public title
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
Query!
Scientific title
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
Query!
Secondary ID [1]
0
0
SB1518-2008-003
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Myelofibrosis
0
0
Query!
Myeloproliferative Disorders
0
0
Query!
Polycythemia Vera
0
0
Query!
Essential Thrombocythemia
0
0
Query!
Condition category
Condition code
Blood
0
0
0
0
Query!
Haematological diseases
Query!
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - SB1518
Treatment: Drugs: SB1518
SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Phase 1: to establish the maximum tolerated dose of SB1518 as a single agent when administered orally daily
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Throughout the study
Query!
Primary outcome [2]
0
0
Phase 2: to assess the clinical benefit rate in subjects with CIMF who are treated with SB1518 at the recommended dose
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Throughout the study
Query!
Secondary outcome [1]
0
0
Assess the safety and tolerability of SB1518, administered orally once daily in subjects with CIMF
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Throughout the study
Query!
Secondary outcome [2]
0
0
Assess the pharmacokinetic profile of SB1518
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Throughout the study
Query!
Secondary outcome [3]
0
0
Assess the pharmacodynamic profile of SB1518
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Throughout the study
Query!
Eligibility
Key inclusion criteria
Inclusion Criteria
- Subjects with CIMF (including post ET/PV MF) requiring therapy, including:
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Men of reproductive potential who can agree to practice effective contraception during
the entire study period and for one month after the last study treatment
- Women of child-bearing potential who have a negative pregnancy test within 14 days
prior to the first dose of study drug and can agree to practice effective
contraception during the entire study period and for one month after the last study
treatment, unless documentation of infertility exists
- Subjects who are able to understand and willing to sign the informed consent form
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria
- Subjects with uncontrolled inter-current illness including, but not limited to,
ongoing active infection, symptomatic congestive heart failure, unstable angina
pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
limit compliance with study requirements as judged by treating physician. Subjects
receiving antibiotics for infections that are under control may be included in the
study unless the antibiotic is a CYP3A4 inducer/inhibitor
- Subjects known to be HIV-positive
- Subjects with known active hepatitis A, B, or C, or latent hepatitis B
- Women who are pregnant or lactating
- Subjects with prior radiation therapy to more than 20% of the hematopoietic marrow
(prior radiation to spleen is allowed)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/08/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/01/2012
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
55
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Peter MacCallum Cancer Centre - Melbourne
Query!
Recruitment hospital [2]
0
0
Royal Melbourne Hospital - Melbourne
Query!
Recruitment hospital [3]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment postcode(s) [1]
0
0
3002 - Melbourne
Query!
Recruitment postcode(s) [2]
0
0
3050 - Melbourne
Query!
Recruitment postcode(s) [3]
0
0
5000 - Adelaide
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Massachusetts
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
S*BIO
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The study consists of two phases: The first portion of the study is a Phase 1 dose escalation
study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when
given as a single agent orally once daily in subjects with Chronic Idiopathic Myelofibrosis
(CIMF) regardless of their JAK2 mutational status. The second portion of the study is a Phase
2 study to define the efficacy and safety profile of single agent SB1518 at the recommended
dose in subjects with CIMF.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00745550
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
John Seymour, M.D.
Query!
Address
0
0
Peter MacCallum Cancer Centre, Australia
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00745550
Download to PDF